Micromet Announces Presentations on BiTE Antibody Programs at AACR Annual Meeting

News provided by

Mar 22, 2010, 08:00 ET

BETHESDA, Md., March 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that 11 presentations will be made by the Company and its collaborators at the American Association for Cancer Research (AACR) 101st Annual Meeting to be held April 17-21, 2010 in Washington, DC.

Presentation details:
Poster Title: "Validation of Cynomolgus monkeys as relevant species for safety
assessment of a novel human BiTE antibody platform for cancer therapy"
Presentation Date/Time: Monday, April 19, 2010, 2 – 5 PM ET
Presenter: Benno Rattel, Micromet
Abstract Number: 2435
Location: Exhibit Hall A – C, Poster Session 18

Poster Title: "Evidence of a therapeutic window with a T cell-engaging BiTE antibody based on
monoclonal antibody cetuximab (Erbitux)"
Presentation Date/Time: Monday, April 19, 2010, 2 – 5 PM ET
Presenter: Ralf Lutterbuese, Micromet
Abstract Number: 2429
Location: Exhibit Hall A – C, Poster Session 18

Poster Title: "Novel primate-crossreactive BiTE antibodies that eliminate cancer cells expressing
cMet, IGFR-1, FAP-alpha, PSCA, endosialin, CAIX or Her2/neu"
Presentation Date/Time: Monday, April 19, 2010, 2 – 5 PM ET
Presenter: Tobias Raum, Micromet
Abstract Number: 2434
Location: Exhibit Hall A – C, Poster Session 18

Poster Title: "Eradication of established pancreatic tumors in mice by engagement of extra-tumoral
human T cells with BiTE antibody MT110"
Presentation Date/Time: Monday, April 19, 2010, 2 – 5 PM ET
Presenter: Matthias Friedrich, Micromet
Abstract Number: 2433
Location: Exhibit Hall A – C, Poster Session 18

Poster Title: "The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a
nonlinear epitope present in the full-length but not a short splice variant of CEA"
Presentation Date/Time: Monday, April 19, 2010, 2 – 5 PM ET
Presenter: Li Peng, MedImmune
Abstract Number: 2584
Location: Exhibit Hall A – C, Poster Session 24

Poster Title: "Inhibition of breast cancer cell proliferation and unique epitope
recognition by EpCAM-specific human monoclonal antibody adecatumumab"
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET
Presenter: Markus Muenz, Micromet
Abstract Number: 5339
Location: Exhibit Hall A – C, Poster Session 19

Poster Title: "Impact of binding epitope and antigen size on the cytotoxic activity of MCSP-specific BiTE antibodies for treatment of melanoma"
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET
Presenter: Claudia Bluemel, Micromet
Abstract Number: 5340
Location: Exhibit Hall A – C, Poster Session 19

Poster Title: "Metastatic colorectal cancer cells from patients previously treated with chemotherapy
are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody"
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET
Presenter: Takuya Osada, Duke University
Abstract Number: 5338
Location: Exhibit Hall A – C, Poster Session 19

Poster Title: "MCSP/CD3 bispecific single-chain antibody construct engages CD4+
and CD8+ T cells for lysis of MCSP-expressing human uveal melanoma cells"
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET
Presenter: Jacobus Bosch, Erlangen University
Abstract Number: 5621
Location: Exhibit Hall A – C, Poster Session 31

Poster Title: "In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel
CEA/CD3-bispecific single-chain BiTE antibody for the treatment of gastrointestinal
adenocarcinomas"
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET
Presenter: Stacey Fuhrmann, MedImmune, LLC
Abstract Number: 5625
Location: Exhibit Hall A – C, Poster Session 31

Poster Title: "Single-chain bispecific BiTE antibody specific for CD3 and
melanoma-associated chondroitin sulfate proteoglycan: In vitro and in vivo anti-melanoma activity"
Presentation Date/Time: Wednesday, April 21, 2010, 8 – 11 AM ET
Presenter: Hans Schoellhammer, John Wayne Cancer Center
Abstract Number: 5626
Location: Exhibit Hall A – C, Poster Session 31

Abstracts can be accessed through the AACR website, www.aacr.org. All posters will be accessible from Micromet's website at www.micromet-inc.com after they are presented.

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Micromet

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com

SOURCE Micromet, Inc.